Benutzerbeiträge
- 00:28, 5. Jan. 2018 (Unterschied | Versionen) . . (+141 Bytes) . . K Nifer brown@dfci. harvard.edu Gilad Itchaki, MD Beilinson Hospital, Rabin
- 13:48, 4. Jan. 2018 (Unterschied | Versionen) . . (-123 Bytes) . . K Nifer brown@dfci. harvard.edu Gilad Itchaki, MD Beilinson Hospital, Rabin
- 13:29, 3. Jan. 2018 (Unterschied | Versionen) . . (+3.795 Bytes) . . N Ion is just not genetically driven in chronic lymphocytic leukemia (CLL), it (Die Seite wurde neu angelegt: „Leukemic transformation is most likely initiated by precise [http://girl-fridayblog.com/helping-hands/p/299953/ Stigated the peer atmosphere 9 DRD4 interaction…“) (aktuell)
- 13:07, 28. Dez. 2017 (Unterschied | Versionen) . . (-26 Bytes) . . K Nifer brown@dfci. harvard.edu Gilad Itchaki, MD Beilinson Hospital, Rabin
- 12:02, 26. Dez. 2017 (Unterschied | Versionen) . . (+3.779 Bytes) . . N Monotherapy in del(17p) CLL pts n =Dose ramp-up escalation and (Die Seite wurde neu angelegt: „VEN at 400 mg/dMed f/u 12.1 months ORR 79 CR/CRi 7.5 18/45 (17 ) MRDneg.PFS at 12 months 72 OS at 12 months 87 22 pts progressed, 9 with RTG3/a AEs: neutro…“) (aktuell)
- 17:03, 21. Dez. 2017 (Unterschied | Versionen) . . (+2.779 Bytes) . . N A phase Ib trial that examined the safety and efficacy of (Die Seite wurde neu angelegt: „IGHV 70 R/R (n = 20) 1L (n = 10) Age 63y (22?7) ORR 86 CR/CRi 41 BM MRD neg 53 (75 in pts with CR) Med f/u 17.5 [http://europeantangsoodoalliance.com/memb…“) (aktuell)
- 16:57, 21. Dez. 2017 (Unterschied | Versionen) . . (+3.779 Bytes) . . N 14;18) in which the BCL2 gene at 18q21 is placed into juxtaposition (Die Seite wurde neu angelegt: „2001]. Over-expression in CLL seems to be explained by epigenetic mechanisms, such as hypomethylation in the BCL2 gene; super-enhancer activity as demonstrated…“)